The Adapter CAR: A novel universal chimeric antigen receptor (CAR) that can turn a biosimilar antibody into a CAR T cell
Ronald P Dudek
Lentigen Technology Inc., USA
: J Nephrol Ren Dis
Abstract
The workshop will start with a review of the chimeric antigen receptor (CAR) and CAR engineered T cells, and segue into an introduction of a novel universal CAR, the Adapter CAR™, that can turn any antibody into a CAR T cell. Most of the workshop will be focused on how to manufacture CAR T cells, including two videos on a novel automated CAR T cell manufacturing solution, the Miltenyi Biotec CliniMACS Prodigy system.
Biography
Ronald P Dudek is a CAR T cell entrepreneur. His latest company, Living Pharma, Inc., was acquired by Lentigen Technology, Inc., where he is employed as Director of Technology Development, Adapter CAR Program Manager. Mr. Dudek has a B.S., Biological Science degree, summa cum laude, from Fordham University, NY, NY and an MBA, Marketing and Finance, from U.C. Berkeley, Berkeley, CA.
E-mail: ron.dudek@lentigen.com
